These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Bevacizumab and ovarian cancer. Sato S; Itamochi H Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222 [TBL] [Abstract][Full Text] [Related]
49. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Shih T; Lindley C Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999 [TBL] [Abstract][Full Text] [Related]
50. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Tao X; Sood AK; Deavers MT; Schmeler KM; Nick AM; Coleman RL; Milojevic L; Gershenson DM; Brown J Gynecol Oncol; 2009 Sep; 114(3):431-6. PubMed ID: 19524286 [TBL] [Abstract][Full Text] [Related]
51. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer. Han ES; Wakabayashi M; Leong L Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484 [TBL] [Abstract][Full Text] [Related]
52. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer. Manegold C Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923 [TBL] [Abstract][Full Text] [Related]
53. The role of bevacizumab in advanced epithelial ovarian cancer. Kroep JR; Nortier JW Curr Pharm Des; 2012; 18(25):3775-83. PubMed ID: 22591420 [TBL] [Abstract][Full Text] [Related]
54. Antiangiogenic therapies in ovarian cancer. Reinthaller A Memo; 2016; 9(3):139-143. PubMed ID: 27752291 [TBL] [Abstract][Full Text] [Related]
55. Antiangiogenic therapy for cancer: an update. Al-Husein B; Abdalla M; Trepte M; Deremer DL; Somanath PR Pharmacotherapy; 2012 Dec; 32(12):1095-111. PubMed ID: 23208836 [TBL] [Abstract][Full Text] [Related]
56. Current status of bevacizumab in advanced ovarian cancer. Tomao F; Papa A; Rossi L; Caruso D; Panici PB; Venezia M; Tomao S Onco Targets Ther; 2013; 6():889-99. PubMed ID: 23901283 [TBL] [Abstract][Full Text] [Related]
57. Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research. Gadducci A; Lanfredini N; Sergiampietri C Crit Rev Oncol Hematol; 2015 Oct; 96(1):113-28. PubMed ID: 26126494 [TBL] [Abstract][Full Text] [Related]
58. Angiogenesis as a strategic target for ovarian cancer therapy. Spannuth WA; Sood AK; Coleman RL Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546 [TBL] [Abstract][Full Text] [Related]
59. Current status on biologic therapies in the treatment of epithelial ovarian cancer. Han ES; Lin P; Wakabayashi M Curr Treat Options Oncol; 2009 Apr; 10(1-2):54-66. PubMed ID: 19381822 [TBL] [Abstract][Full Text] [Related]
60. Recent concepts of antiangiogenic therapy. Konno H; Yamamoto M; Ohta M Surg Today; 2010 Jun; 40(6):494-500. PubMed ID: 20496129 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]